Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Discussant: LIBerate-OLE, LIBerate-HeFH_OLE
Logo

American Heart Association

  123
  0

Final ID:

Discussant: LIBerate-OLE, LIBerate-HeFH_OLE

  • O'donoghue, Michelle  ( BRIGHAM WOMENS HOSP , BOSTON , Massachusetts , United States )
    • Author Disclosures:
    Michelle O'Donoghue: DO have relevant financial relationships ; Consultant:Janssen:Active (exists now) ; Consultant:NovoNordisk:Active (exists now) ; Consultant:Verve:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Researcher:AstraZeneca:Active (exists now) ; Researcher:Marea:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Amgen:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

Discussant: PALISADE

Shapiro Michael

More abstracts from these authors:
The New Guideline in a Global Context: Writing Committee Reply

O'donoghue Michelle, Sandner Sigrid, Tamis-holland Jacqueline

Lp(a) and ASCVD: What does the causal link mean for risk reduction in practice?

O'donoghue Michelle

You have to be authorized to contact abstract author. Please, Login
Not Available